Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. LFCR
stocks logo

LFCR

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q3
FY2026Q4
35.31M
+0.44%
-0.160
-65.96%
31.60M
-13.29%
-0.210
+250%
Estimates Revision
The market is revising No Change the revenue expectations for Lifecore Biomedical, Inc. (LFCR) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 3.19%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Up
up Image
+3.19%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Lifecore Biomedical Inc (LFCR.O) is -9.25, compared to its 5-year average forward P/E of -65.96. For a more detailed relative valuation and DCF analysis to assess Lifecore Biomedical Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-65.96
Current PE
-9.25
Overvalued PE
231.87
Undervalued PE
-363.78

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
23.45
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
42.05
Undervalued EV/EBITDA
4.85

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
1.64
Current PS
0.00
Overvalued PS
2.11
Undervalued PS
1.17
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

LFCR News & Events

Events Timeline

(ET)
2025-11-06
16:55:42
Lifecore supports revenue outlook of $74M-$76M during transition period
select
2025-11-06
16:54:19
Lifecore Announces Q3 Earnings Per Share of 29 Cents, Below Consensus Estimate of 31 Cents
select
2025-10-29 (ET)
2025-10-29
07:20:16
Lifecore Enters Partnership with Major International Pharmaceutical Firm
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
1.0
10-13Newsfilter
Lifecore Biomedical to Attend Upcoming Industry Conferences and Events

  • Upcoming Industry Events: Lifecore Biomedical will participate in three major conferences: the 15th Annual Partnership Opportunities in Drug Development (PODD) in Boston, CPHI Worldwide in Frankfurt, and the American Pharma Manufacturing & Outsourcing Summit in Boston.

  • Company Profile: Lifecore Biomedical is a contract development and manufacturing organization specializing in sterile injectable pharmaceutical products, with over 40 years of experience in the biopharmaceutical sector.

[object Object]
Preview
3.0
10-02NASDAQ.COM
Explore the Details: DWAS Offers a 16% Potential Gain

  • ETF Performance Analysis: The Invesco Dorsey Wright SmallCap Momentum ETF (DWAS) has an implied analyst target price of $107.40, indicating a potential upside of 16.14% from its current trading price of $92.48.

  • Notable Holdings with Upside: Key underlying holdings of DWAS, such as Lifecore Biomedical Inc (LFCR), BrightView Holdings Inc (BV), and ASP Isotopes Inc (ASPI), show significant upside potential based on analyst target prices, with expected increases of 39.47%, 34.58%, and 21.01% respectively.

[object Object]
Preview
7.0
09-27Globenewswire
LIFECORE INVESTIGATION NOTICE: Bragar Eagel & Squire, P.C. is Looking into LifeCore Biomedical, Inc. for Long-Term Shareholders and Urges Investors to Reach Out to the Firm

  • Investor Alert: Bragar Eagel & Squire, P.C. is investigating potential claims against LifeCore Biomedical, Inc. (NASDAQ: LFCR) for long-term stockholders who may have suffered losses between October 7, 2020, and March 19, 2024, following a class action complaint filed on July 29, 2024.

  • Allegations Against LifeCore: The complaint alleges that LifeCore's board of directors made false and misleading statements regarding the company's financial health, including deficiencies in internal controls and inaccurate financial reporting, which may have misled investors about the company's true prospects.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Lifecore Biomedical Inc (LFCR) stock price today?

The current price of LFCR is 7.77 USD — it has increased 1.7 % in the last trading day.

arrow icon

What is Lifecore Biomedical Inc (LFCR)'s business?

Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO). The Company designs, develops, manufactures and sells differentiated products for biomaterials markets and license technology applications to partners. The Company offers highly differentiated capabilities in the development, fill and finish of sterile, injectable-grade pharmaceutical products in syringes and vials. It is involved in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a spectrum of medical conditions and procedures. The Company uses its fermentation process and aseptic formulation and filling expertise to develop HA-based products for multiple applications and to take advantage of non-HA devices and drug opportunities.

arrow icon

What is the price predicton of LFCR Stock?

Wall Street analysts forecast LFCR stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for LFCR is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Lifecore Biomedical Inc (LFCR)'s revenue for the last quarter?

Lifecore Biomedical Inc revenue for the last quarter amounts to 31.11M USD, increased 25.92 % YoY.

arrow icon

What is Lifecore Biomedical Inc (LFCR)'s earnings per share (EPS) for the last quarter?

Lifecore Biomedical Inc. EPS for the last quarter amounts to -0.29 USD, decreased -45.28 % YoY.

arrow icon

What changes have occurred in the market's expectations for Lifecore Biomedical Inc (LFCR)'s fundamentals?

The market is revising No Change the revenue expectations for Lifecore Biomedical, Inc. (LFCR) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 3.19%.
arrow icon

How many employees does Lifecore Biomedical Inc (LFCR). have?

Lifecore Biomedical Inc (LFCR) has 406 emplpoyees as of December 05 2025.

arrow icon

What is Lifecore Biomedical Inc (LFCR) market cap?

Today LFCR has the market capitalization of 291.11M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free